386 results about "In vitro test" patented technology

Techniques are provided for processing in vitro test sample data. The in vitro test sample data is accessed and additional data may be accessed, such as from an integrated knowledge base (12), from a plurality of controllable and prescribable data resources (40). Analysis (440; 448) of the data is performed, such as via an automated computer-assisted data operating algorithm (22) to identify features of interest available or possibly available from the in vitro test data. Processes (446; 454; 458; 460) are performed, either on the data or upon an in vitro sample based upon the analysis. Results of the processing may include acquisition (438) of additional test samples, modification (444; 452) of processing of test samples or of sample data, and so forth.

Mild shampoo compositions are described that are economical, have excellent in-use properties, and provide enhanced conditioning benefits. The compositions have low ocular irritation potential and are particularly suitable for use by children. The compositions include a surfactant system composed on an alkyl ethoxy sulfate having at least 3 ethylene oxide groups, a betaine surfactant, and an hydroxysultaine surfactant in specific ratios; and a non-volatile water-insoluble silicone. In-vitro tests are described that allows selection of optional ingredients that do not compromise the mildness or hair conditioning performance of the composition.

The invention relates to a synbiotics of bacillus licheniformis and oligosaccharide class prebiotics and a composite and a formulation thereof, being characterized in that the synbiotics comprises bacillus licheniformis medical live bacterial powder and the oligosaccharide class prebiotics, wherein the bacillus licheniformis medical live bacterial powder contains live bacteria about 30 billion/gram; the weight ratio of the bacillus licheniformis medical live bacterial powder to the oligosaccharide class prebiotics is 1:1 to 76; the weight ratio of the medical live bacterial powder of the composite, the oligosaccharide class prebiotics and auxiliary materials is as follows: 1.25-5 percent of the bacillus licheniformis medical live bacterial powder, 5-95 percent of the oligosaccharide class prebiotics, 20-50 percent of preferable oligosaccharide class prebiotics, 30-65 percent of diluting agents, 1-20 percent of bonding agents, 1-15 percent of disintegrating agents, 0.1-3 percent of lubricating agents, 1-10 percent of coating agents, 0.01-0.1 percent of flavoring agents, 0.0001-0.001 percent of coloring agents, and 0.1-15 percent of suspending agents. The synbiotics composite is prepared into oral common tablets, oral cavity disintegration tablets, dispersing tablets, enteric-coated tablets, granular formulation, enteric-coated granular formulation, capsules, enteric-coated capsules, dry supensoid agents and external tablets according to a conventional process; and an in vitro test shows that each formulation can promote the growth and the reproduction of the synbiotics of bacillus licheniformis, restrain the growth of harmful bacteria, enhance the immunizing power of parasitifers, reduce diarrhea and enhance the health care.

A Lactobacillus plantarum BB9 capable of adhering to gastrointestinal tract and cholesterol removal is isolated from fruits and exhibits high BSH activity. In-vitro tests demonstrate that Lactobacillus plantarum BB9 has good acid and bile tolerance, and strong ability to adhere to intestinal cells. In-vivo tests show that hamsters fed high cholesterol diets added with BB9 strain have cholesterol and triglycerides in blood and liver effectively reduced, and their HDL-c/LDL-c ratios in blood are significantly higher than those of hamsters fed Lactobacillus acidophilus ATCC 43121 strain. It is hoped that the excellent acid and bile tolerance and intestinal adherence of the lactobacillus strain provided herein could produce cholesterol-lowering effect in humans.

The invention relates to a 5-site or 6-site substituent naphthalimide compound and antitumor applications thereof, which belongs to the fine chemical field. The compound is characterized in that various aliphatic amidogen, heterocyclic amidogen, aryl and Ar aryl are respectively introduced into the 5-site or 6-site of the naphthalimide by a nucleophilic substitution reaction to obtain small molecule compound similar to a lead compound amonafide structure. The small molecule compound has obvious inhibiting activity in vitro test on Hela and P388D1, and wherein, some compounds have stronger cytotoxicity than the amonafide under the same test conditions. In addition, the structures of the compounds take on diversity; the compounds without acetylation sites can be prevented from having the side effect similar to the amonafide; the other compounds with the acetylation sites can be prevented from having the side effect by personalized administration, therefore, the compound has medical application prospect in curing diseases related to tumors.

The invention relates to a DNA-targeted o-dicyano-acenaphtho pyrazine compound in the field of application of antineoplastic medicaments. The compound is prepared by taking acenaphthene quinone as a raw material and performing bromination, cyclization and aromatic nucleophilic substitution reaction. The compound is characterized in that: one end takes an amino straight chain of a flexible side chain or an annular group as an electron-donating group, while the other end takes two cyanogen groups as electron-withdrawing groups; the two ends form an electron deficient large-plane conjugated system; and the structure accords with an ideal DNA intercalator. The compound shows obvious inhibitory activity to an in vitro test of MCF-7 (human mammary cancer cells).

The invention relates to separation, selection and identification of lactobacilli having a function of inhibiting activity of alpha-glucosidase, in particular to a lactobacillus plantarum and an application thereof. Lactobacilli are separated out from intestinal canals of longevous people in Bama of Guangxi; on the basis of comprehensive comparison of acid resistance, cholate resistance, in-vitro antioxidant ability and sensitivity to antibiotics, a strain having a best inhibition function to activity of alpha-glucosidase is selected out by means of in-vitro tests; the strain is identified as Lactobacillus plantarum Grx16 by means of physiological and biochemical tests, API reagent strips and 16s rDNA sequencing analysis. The lactobacillus plantarum Grx16 can be used for preparation of fermented milk having the function of inhibiting activity of alpha-glucosidase.

In vivo testing for analytes in a life-form is an attractive concept because a biological sample does not have to be removed from the life-form. However, in vivo testing alone is unable to provide information that is accurate, complete and/or reliable enough to safely replace in vitro testing. In contrast to performing either in vivo or in vitro testing independently and alone, some embodiments of the present invention provide a joint-diagnostic apparatus for combined in vivo and in vitro testing. In some specific embodiments results from an in vitro measurement module are used in combination with subsequent in vivo measurements/observations obtained at a later time, and/or vice versa. Accordingly, in some embodiments in vitro measurements are used to compliment and/or partially compensate for some of the limitations of in vivo testing, and at the same time enabling some of the benefits of in vivo testing by reducing the number of biological samples taken.

The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.

The invention discloses a new secretive cytokine NS128 of human beings, which relates to a coding amino acid sequence of the cytokine or the polynucleotide of the cytokine fragment, containing a genetic engineering carrier and a host cell of the polynucleotide. The invention also relates to a production method of the amino acid sequence of the cytokine or the polypeptide of the cytokine fragment and the production method of the polypeptide as well as a small interference RNA, which suppresses the expression of the cytokine. The invention also relates to a salt which contains the polynucleotide or the salt of acceptable drugs, or a medical composition of the polypeptide or the salt of acceptable drugs. The invention further relates to applications of the polynucleotide of the cytokine, the polypeptide or the small interference RNA in preparation of prevention and/or treatment medicines for tumor, infection, hematopoietic disorder and autoimmune disease, etc., in particular having clinical implications for tumor, inflammation and nervous system disease and so on related to MAPK signal pathway. The invention also relates to a method of in vitro testing whether the expression of the polynucleotide or the polypeptide changes. The invention also relates to a monoclonal or polyclonal antibody which is specifically bound with the polypeptide or an active fragment of the polypeptide.

The in vitro test device and test method for the fatigue performance of the self-expanding cavity stent is a complete set of methods suitable for testing the fatigue performance parameters of the stent in vitro. The self-expanding cavity stent fatigue performance testing device is mainly composed of four parts: man-machine Interfaces, controls, actuators, and machine vision. The PC of the human-machine interface is connected to the output port of the data acquisition card and the input port of the image acquisition card. The data acquisition card controls the operation of the execution device. The execution device mainly includes a loading device, a peristaltic device and a thermostat. The loading device is arranged in parallel The wires are used to fix the stent, and the stent is loaded to simulate the long-term radial annular contraction pressure of various lumens on the stent.

This invention is a model that simulates the complexity of biological signaling in a cell in response to radiation therapy. Using gene expression profiles and radiation survival assays in an algorithm, a systems model was generated of the radiosensitivity network. The network consists of ten highly interconnected genetic hubs with significant signal redundancy. The model was validated with in vitro tests perturbing network components, correctly predicting radiation sensitivity 2/3 times. The model's clinical relevance was shown by linking clinical radiosensitivity targets to the model network. Clinical applications were confirmed by testing model predictions against clinical response to preoperative radiochemotherapy in patients with rectal or esophageal cancer.

The invention discloses a composition with skin-whitening and anti-ageing effects, a skin care product containing the composition as well as a preparation method and an application of the composition. The composition is prepared from the following components: 0.2%-10.0% of L-ascorbic acid 2-glucoside, 0.1%-0.2% of superoxide dismutase, 0.1%-0.5% of a grape seed extract, 0.1%-0.5% of a soybean fermentation extract, 10%-30% of propanediol, 0.1%-0.2% of aloe powder and the balance amount of water. An experimental result shows that the composition has the skin-whitening and anti-ageing effects, the method is easy in operation, the production cost is low, and the product stability is high; an evaluation on an in vitro test and a human body skin test proves that the composition has good skin-whitening and anti-ageing effects and is safe and free from side effects; meanwhile, the composition and the skin care product containing the composition, provided by the invention, also have better long-lasting hydrating effects.

A novel population of multipotent cardiac precursor (MCP) cells derived from human blastocysts derived stem cells is disclosed, methods for the preparation thereof and use of the cells for in vitro testing. Basement cells derived from hBS cells are also disclosed and method for the preparation of MCP cells from basement cells. The MCP cells have the following characteristics

• • i) at least 1% of the cells exhibit no antigen expression of one or more markers for undifferentiated cell, the marker being selected from the group consisting of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81 and Oct-4,
  • ii) at least 1% of the cells exhibit no protein expression of one or more of a neural marker including nestin or GFAP
  • iii) at least 1% of the cells exhibit protein and/or gene expression of one or more of a mesodermal marker including brachyury, vimentin or desmin
  • iv) at least 1% of the cells exhibit protein and/or gene expression of Flk-1 (KDR).

Furthermore, the MCP cells have a characteristic morphology. They grow as clusters of small, round and phase-bright cells; individual cells are 5-20 μm in diameter and each cluster is composed of 2-500 cells. They form clusters of round or elongated shape, that appear as loosely adherent cell clumps that as illustrated in FIG. 2 panel a, b and c. Furthermore, they have a relatively high nucleus-to-cytoplasma ratio, e.g. 1:2-1:64 of the total volume of the cell and/or appear as balloons on a string, as illustrated in FIG. 18, schematic sketch. Moreover, the MCP cells are non-contracting.